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RESUMO – A imunossupressão crónica é um reconhecido factor de risco para a tuberculose. O nosso objectivo foi 
o de obter um consenso para o rastreio e prevenção da tuberculose em portadores de doenças inflamatórias imuno-
mediadas candidatos a terapêutica biológica. Métodos: Revisão crítica da literatura e opinião de peritos acerca das 
terapêuticas imunossupressoras e risco de tuberculose. Resultados e Conclusão: O método actualmente recomenda-
do para o rastreio é o teste cutâneo da tuberculina e o doseamento do interferão gama, após exclusão da tuberculo-
se activa. Doentes com rastreio positivo devem receber tratamento para a tuberculose latente. Estes doentes podem 
iniciar a terapêutica biológica após 1 a 2 meses, desde que a sua adesão seja rigorosa e apresentem boa tolerância 
à terapêutica profilática. 
PALAVRAS-CHAVE – Tuberculose latente; Terapêutica biológica; Terapêutica anti-TNF; Doenças inflamatórias imu-
no-mediadas.
POSITION PAPER ON TUBERCULOSIS SCREENING IN PATIENTS 
WITH IMMUNE MEDIATED INFLAMMATORY DISEASES 
CANDIDATES FOR BIOLOGICAL THERAPY 
ABSTRACT – Chronic immunosuppression is a known risk factor for tuberculosis. Our aim was to reach a consensus on 
screening and prevention of tuberculosis in patients with immune mediated inflammatory diseases candidates to biolo-
gic therapy. Methods: Critical appraisal of the literature and expert opinion on immunosuppressive therapies and risk of 
tuberculosis. Results and Conclusion: The currently recommended method for screening is the tuberculin skin test and 
the interferon gamma assay, after exclusion of active tuberculosis. Positively screened patients should be treated for la-
tent tuberculosis infection. Patients may start biological therapy after 1 to 2 months, as long as they are strictly adhering 
to and tolerating their preventive regimen.
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INTRODUCTION
In populations with high incidence of tuberculosis 
(TB), there have been an increased number of TB cases 
reported in patients treated with tumor necrosis factor 
antagonists (anti-TNF)1 . In fact, the relative risk (RR) of 
developing TB is 1.6-25.2 times higher in Rheumatoid 
Arthritis (RA) patients under anti-TNF therapy than in RA 
patients treated with conventional immunosuppressive 
therapy, depending on the clinical setting and the anti-
-TNF used1-7. 
Active TB in the context of anti-TNF therapy usually 
results from the reactivation of a latent infection, shor-
tly after the beginning of the treatment5,8. TB often pre-
sents an atypical behaviour, which may pose difficulties 
to the diagnosis9. In countries with high incidence of TB, 
cases caused by new infection are also particularly fre-
quent. TNF is fundamental for the immunological de-
fence against Mycobacterium tuberculosis, especially in 
the formation and maintenance of granulomas. Animal 
models confirmed that it is possible to reactivate TB after 
administering anti-TNF antibodies10.
Besides anti-TNFs, other biological agents were ap-
proved for immune mediated inflammatory disease’s 
treatment. Data on the risk of developing TB infection 
in patients treated with these other agents are scar-
ce. Even though this risk might be lower for some of 
the biological agents that do not interfere with TNF 
until more data is available this group assumed that 
this position paper should be applied to all biological 
treatments.
Preventive chemotherapy can significantly reduce the 
incidence of active TB in individuals with latent infec-
tion, identified by positive tuberculin skin test (TST) or 
interferon-γ release assay (IGRA)11. 
The currently available evidence about the best ma-
nagement to prevent TB in patients receiving biolo-
gical therapy is limited. In this position paper on the 
screening and prevention of TB in patients treated with 
biological therapy, delegates from the Tuberculosis 
Committee (TC) of the Portuguese Pulmonology Society 
(SPP), the Rheumatoid Arthritis Study Group (GEAR) of 
the Portuguese Society of Rheumatology (SPR), the Portu-
guese Society of Dermatology and Venereology (SPDV) 
and the Portuguese Society of Gastroenterology (SPG), 
have revised and updated recommendations that had 
been previously developed by the GEAR-SPR and by the 
TC–SPP, first published in 200612 and latter updated in 
200813.
The main objective of this position paper is to contri-
bute for the reduction of the number of cases of reacti-
vated TB and new TB infections in patients with immune 
mediated inflammatory diseases who are candidates for 
treatment with biological therapy in Portugal. An addi-
tional objective is to standardize the procedures used to 
screen and prevent TB in the initial assessment of these 
patients, preferably at disease onset, before the begin-
ning of any immunosuppressant therapy.
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Who should be screened?
All patients with immune mediated inflammatory 
diseases candidates for the use of biological therapy 
should be screened for latent TB infection (LTBI) prior to 
starting therapy (Evidence level C).
Patients eligible for anti-TNF therapy have an increa-
sed risk of developing TB upon starting this treatment. 
TB in this setting can present with severe, atypical and 
life-threatening manifestations. This risk exists not only 
due to the biological importance of TNF in the initiation 
and maintenance of the response against Mycobacte-
rium tuberculosis, but also because the underlying di-
seases (eg. RA) and concomitant treatments (eg. steroid 
therapy) increase the risk of TB per se14-18. Most of the 
active TB cases in patients treated with anti-TNF are due 
to reactivation of LTBI. It is well known that screening 
for LTBI before starting anti-TNF therapy is effective in 
preventing reactivation of TB17. Therefore, all national 
guidelines recommend the exclusion of active TB disea-
se and LTBI in patients in whom biological therapy is 
considered19-21.
When to screen?
Patients with immune mediated inflammatory disea-
ses should be screened for TB before starting biologic 
treatment and ideally when the disease is diagnosed 
(Evidence level C)
Any candidate to biological therapy should be scree-
ned for the presence of specific immune response to 
M. tuberculosis (including TST and IGRA) before starting 
these drugs and ideally when the immune mediated in-
flammatory disease is diagnosed, except in patients with 
mild forms of psoriasis, treated with topical drugs19-21. 
It has been shown that certain diseases, such as RA, 
as well as chronic immunosuppressive therapy, such as 
corticosteroids (> 15mg/day for more than 2 weeks) 
increase the risk of TB. In addition, it is also well known 
that immunosuppressive therapy compromises the sen-
sitivity of the TST and IGRA, being this especially true for 
TST16,18,22-25. Therefore, it is highly desirable that the first 
screen for TB should be done at the moment of diagno-
sis, before any kind of immunosuppressive treatment or 
phototherapy is started.
Which tests should we use?
After exclusion of active TB, LTBI should be screened 
with TST and IGRA (Evidence level C and D)
In the light of current knowledge, and in the ab-
sence of a gold standard test for LTBI diagnosis19, the 
screening process for LTBI requires a combination of a 
detailed medical history (which should include ethnicity, 
country of birth, history of or recent exposure to TB, pre-
vious TB and respective treatment, co-morbidities asso-
ciated with increased risk of TB, professional activities 
with increased risk of exposure to TB), travel to endemic 
areas, chest radiograph (searching for changes indica-
tive of active or residual previous TB) and tests for im-
munological memory against M. Tuberculosis (TST and 
IGRA)19. In erythrodermic psoriasis TST may be impos-
sible to perform, reinforcing the need of IGRA in these 
cases. 
The sensitivity of both tests may be compromised in 
patients receiving immunosuppressive therapy, althou-
gh published evidence suggests that IGRA has a higher 
sensitivity than TST in patients with immune mediated 
inflammatory diseases, even after starting immunosup-
pressive therapy26-30.
Currently, different guidelines are adopted regar-
ding the use of TST and IGRA, reflecting the difficul-
ty of choosing the best strategy19,31-33. Overtreatment, 
implying the risk of drug toxicity due to a false-positive 
screening and undertreatment due to a false-negative 
screening are the main concerns.
Since the increase in sensitivity and specificity pro-
vided by IGRA in different studies is controversial and 
their positive and negative predictive values are yet to 
be defined, the role of IGRA is still under investigation. 
In this sense, IGRA cannot yet be used as a single test for 
immunological memory to M. Tuberculosis. Thus, cur-
rently it is prudent to use both TST and IGRA in order to 
maximize sensitivity19,31,32. 
Since patients may have false negative TST due to 
immunossupression, a two step approach is advised – 
repeat TST 1-3 weeks after the initial negative screening. 
How to exclude active TB in patients with 
Crohn’s disease?
Acid fast bacilli smear and culture should be perfor-
med in endoscopic biopsies (Evidence level C)
The distinction between Crohn's disease and intesti-
nal TB is a diagnostic challenge, as they present similar 
clinical, radiological, endoscopic and histological fea-
tures.
Investigation of patients with suspected Crohn’s di-
sease should always include differential diagnosis with 
intestinal TB. Acid fast bacilli smear and culture are 
warranted in pathological examination of endoscopic 
biopsies. Other tests such as nucleic acid amplification, 
immunohistochemistry or in situ hybridization are pro-
mising techniques that have been evaluated in some 
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studies, but they are not widely available and require 
further validation35-52. 
How to interpret the TST?
TST is considered positive if induration is ≥5mm in 
previously immunossuppressed patients and if ≥10mm 
in patients not previously exposed to immunossuppres-
sors. (Evidence level D)
In order to increase the sensitivity of TST (at the expen-
se of lower specificity) different guidelines recommend, 
in the immunocompromised population, an induration 
of ≥5mm to be the cut-off for a positive TST19,21,53,54.
The Tuberculosis Network European Trials Group 
(TBNET) recommends a cut-off value of 10mm, stating 
that the loss of sensitivity to detect infection by increasing 
the cut-off from 5 to 10mm is marginal, while the gain 
in specificity is substantial19. Taking this into conside-
ration, TBNET suggests that a TST ≥ 10mm should lead 
to LTBI treatment, without requiring IGRA confirmation. 
This evidence is based on results of non controlled and 
non randomized trials and on observational studies.
According to the Portuguese clinical practice, patients 
with immune mediated inflammatory diseases, who are 
candidates for anti-TNF therapy, should undergo a TST: 
the test is considered positive in previously immunos-
suppressed patients if the induration is ≥5mm and in 
patients not previously exposed to immunossuppressors 
if the induration is ≥10mm.
Who should start LTBI treatment? 
Patients with epidemiological risk factors for TB (his-
tory of exposure to TB, previous TB, emigrants from 
high TB prevalence areas, residents in high incidence 
areas, co morbidities associated with increased risk of 
TB, professional activities with increased risk of exposure 
to TB, travel to endemic areas), or chest X-ray sequelae 
of untreated previous TB, or positive TST and/or IGRA, 
should start LTBI treatment, after exclusion of active TB. 
(Evidence level C and D).
Whenever there is evidence of exposure to TB (regar-
dless the results of the screening and after exclusion of 
active TB) or LTBI (positive TST and/or IGRA or changes 
in chest radiograph suggestive of previous untreated 
TB), after exclusion of active TB, preventive treatment 
should be offered before initiating biological therapy, 
as these patients have a high risk of progression to di-
sease19,21,55,57,58. 
Due to the risk of serious forms of disease, treatment 
must be offered to candidates for biological therapy re-
gardless of age and presumed date of infection. 
Which LTBI treatment regimen should be 
used?
Isoniazid for 9 months (Evidence level C and D):
Several therapeutic strategies have been proposed. 
Isoniazid is classically recommended as this drug in im-
munocompromised patients has proven to be effective 
(data derived from multiple studies in HIV patients)59-61. 
Isoniazid for a period of 9 months is the most commonly 
used regimen and has an estimated efficacy of around 
90%. This regimen is recommended by the American 
Thoracic Society (ATS)62 and Canadian Tuberculo-
sis Standards63, while the 6 months regimen, in which 
effectiveness varies between  65-69%, is proposed by 
the National Institute for Health and Clinical Excellence 
(NICE)64.
TBNET recommends treatment with isoniazid for 9 
to 12 months or isoniazid and rifampicin for 3 months 
(3HR)19. However, the later is associated with a lower 
efficacy (around 60%). Some studies indicate that 4 
months of rifampicin (4R) are at least as effective as 
3HR and this regime has the advantage of being bet-
ter accepted by patients, having fewer adverse effects 
when compared with regimens based on isoniazid and 
is associated with a lower cost to the health system65-69. 
These are very relevant advantages but effectiveness re-
mains uncertain, as this regimen has not yet been tested 
extensively in randomized trials.
In light of current knowledge, treatment with isonia-
zid for 9 months is the most consensual option19,60,61. 
One month is defined as the minimum LTBI treatment 
duration before starting biological drugs19. This recom-
mendation is based on expert opinion.
Evaluation of the risk for toxicity due to LTBI 
treatment
Patient education, clinical monitoring, baseline and 
monthly laboratory testing of liver enzymes (Evidence 
level C and D):
Given the high risk of TB in patients starting anti-TNF, 
the risk of age-related hepatotoxicity70 should not pre-
vent patients from receiving treatment for LTBI. In addi-
tion to liver toxicity, isoniazid is associated with toxicity 
to the nervous system71. Vitamin B6 reduces central and 
peripheral effects of isoniazid and should be given to 
individuals with a history of alcoholism, diabetes, preg-
nant, postpartum, infants, malnourished, HIV-positive, 
people with active liver disease, cancer or history of pre-
-existing peripheral neuropathy72.
In case of choosing rifampicin-based regimens, in-
teractions with other drugs should be considered, since 
this drug is a potent inducer of CYP45073.
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Besides patient education and clinical monitoring, 
baseline and monthly (or biweekly) laboratory testing 
of liver enzymes is recommended for people older than 
35 years, chronic alcohol abusers, HIV-infected per-
sons, females during pregnancy and within 3 months 
after delivery and for those with chronic liver disease or 
taking potentially hepatotoxic concomitant medications. 
Transient transaminase elevations are common and 
may reflect the process of hepatic adaptation. Howe-
ver, isoniazid and/or rifampicin should be withheld as 
recommended if the serum transaminase level is higher 
than three times the upper limit of normal in a sympto-
matic patient or five times the upper limit of normal in 
the absence of symptoms61,62.
A change of the therapeutic regimen for a less he-
patotoxic one (as 4R, at the expense of effectiveness) 
should be considered when serious hepatotoxicity is li-
miting LTBI treatment with isoniazid.
How should follow up be performed?
Patients should be re-screened for LTBI if the pre-
vious screen had been negative and the patient had not 
started biologicals, to exclude possible infection in the 
meantime (in the absence of a known contact with a 
TB patient, the screen would be valuable for 6 months).
In the event of contact with active TB, TB screening 
should be promptly performed and in the absence of 
disease and LTBI, chemoprophylaxis should be guaran-
teed19.
Annual testing is recommended for patients, who 
live, travel or work in environments where TB exposu-
re is likely, while they continue treatment with biologic 
agents. Patients who tested positive for TST and IGRA 
should only be monitored for clinical signs of TB. 
SUMMARY
1. All candidates for biologic therapy should be scree-
ned for TB.
2. TB screening procedures should include risk asses-
sment, evaluation of TB signs and symptoms, chest 
radiography, TST and IGRA.
3. After exclusion of active TB, the presence of a po-
sitive TST (≥ 10 mm in immunocompetent or ≥ 5 
mm in immunocompromised conditions) or positive 
IGRA indicates the possibility of LTBI and LTBI thera-
py should be offered.
4. The existence of an untreated or inadequately trea-
ted previous TB (determined by chest X-ray sequelae 
and/or clinical history) should be evaluated for active 
TB and, if that is excluded, LTBI treatment should be 
given.
5. In the event of a recent exposure to a TB patient, LTBI 
therapy should be offered, even in the presence of 
negative screening tests.
6. The recommended regimen for LTBI treatment is 9 
months of isoniazid.  
7. Annual testing is recommended while on biological 
treatment.
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